Business
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers,
About this update from Benitec Biopharma Inc.
[{"type":"text","content":"-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and interim clinical study results for the first Cohort 2 Patient will be reported in a late-breaking poster presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference on March 9, 2026- HAYWARD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (\"ddRNAi\") platform, today announced the acceptance of a late-breaking abstract for the BB-301 Phase 1b/2a Clinical Treatment Study ongoing in Oculopharyngeal Muscular Dystrophy Patients (OPMD) with moderate dysphagia. Interim clinical study results for Patients enrolled into Cohort 1 and Cohort 2 will be discussed in a poster presentation at the Muscular Dystrophy Association Clinical and Scientific Conference, being held in Orlando, Florida on March 9, 2026. “We are pleased to present long-term clinical study results for Patients treated with BB-301 in Cohort 1 and interim clinical study results for the first Patient treated with BB-301 in Cohort 2 at the Muscular Dystrophy Association Clinical & Scientific Conference,” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec. “We are grateful to the OPMD community and investigators, and we look forward to providing updates on the ongoing clinical study and future discussions with the FDA as we work toward confirming the pivotal study path for BB-301.” Late-Breaking Poster Presentation: An interim clinical study update for the Phase 1b/2a Clinical Treatment Study of BB-301 in OPMD subjects with moderate dysphagia will be provided in a late-breaking poster presentation, (poster number 501 LB) entitled “Durable Responses to Low-Dose BB-301 in Oculopharyngeal Muscular Dystrophy at 12- and 24-months and Improved Depth of Response to High-Dose BB-301” during poster sessions from 10:15-10:45 am, 12:00-1:30 pm, 3:30-4:00 pm and 6:00-8:00 pm Eastern Time on March 9th in the Exhibit Hall at the 2026 Muscular Dystrophy Association Clinical & S...